Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer
Keywords
Abstract
Description
Advances in systemic treatment led to improved overall survival in patients with metastatic breast cancer. Various studies suggest that by obtaining loco-regional control, overall survival in advanced disease can further be improved.
Pre-operative chemotherapy can be used in metastatic breast cancer to make radical removal of the primary tumor feasible, while simultaneously maintaining control of already present metastatic sites. The doxorubicin and cyclophosphamide regimen (AC) is well-known both in (neo-)adjuvant setting as in treatment of metastatic breast cancer. At present, optimal local control in advanced breast cancer using adequate dosing of doxorubicin is hampered by its toxic systemic effects. Therefore the investigators aim to increase doxorubicin deposition in the primary tumor without interfering with systemic efficacy and toxicity, by combining lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) with local mild hyperthermia, induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU). When heated to 40-43 ºC, ThermoDox releases a very high concentration of doxorubicin locally within seconds. In the absence of hyperthermia, ThermoDox leads to a similar biodistribution and antitumor efficacy to free doxorubicin. MR-HIFU allows for controlled heating of deep-seated tumors.
This is a single-arm phase I feasibility study in 12 patients with de novo stage IV (distant metastasis at the time of diagnosis) her2-negative breast cancer, who have not received previous chemotherapy. The study treatment consists of up to 6 cycles at 21-day intervals of ThermoDox (50mg/m2) administered during MR-HIFU induced hyperthermia (60 minutes at 40-42 ᵒC) and cyclophosphamide (600 mg/m2) administered afterwards. A dedicated MR-HIFU breast system integrated with a clinical 1.5 Tesla Magnetic Resonance Imaging (MRI) scanner will be used for safe and controlled heating of the tumour. Primary endpoints are safety, tolerability and feasibility. Secondary endpoint is efficacy, assessed by radiological response of the local tumor and the distant metastases.
In the Biobank side study, extra blood samples will be collected. These samples will be used for further research on not yet determined topics related to breast cancer.
Dates
| Last Verified: | 02/29/2020 |
| First Submitted: | 11/08/2018 |
| Estimated Enrollment Submitted: | 11/19/2018 |
| First Posted: | 11/20/2018 |
| Last Update Submitted: | 03/09/2020 |
| Last Update Posted: | 03/11/2020 |
| Actual Study Start Date: | 02/29/2020 |
| Estimated Primary Completion Date: | 02/28/2022 |
| Estimated Study Completion Date: | 02/28/2022 |
Condition or disease
Intervention/treatment
Drug: Study treatment
Procedure: Study treatment
Drug: Study treatment
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Study treatment LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide
Single arm study | Drug: Study treatment Patients will receive up to six cycles at three-weeks intervals of:
Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment
60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour
Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment
In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol. |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | Female |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: Patients must meet all of the following inclusion criteria: 1. Histologically confirmed adenocarcinoma of the breast and planned for palliative chemotherapy with doxorubicine en cyclophosphamide 2. Biopsy-proven stage tumor 1-2, any nodes, metastasis 1 (T1-2AnyNM1) at diagnosis of breast cancer. 3. Non-pregnant, non-lactating female at least 18 years of age. If patient is of child-bearing age, she must have a negative serum pregnancy test prior to enrollment and must agree to practice an acceptable form of birth control while on study. 4. The tumor is located within the reach of the HIFU beam (based on pre-treatment Dynamic Contrast Enhanced (DCE-) MRI findings). 5. The distance of the tumor from the skin, nipple, and pectoral wall is at least 1.0 cm (based on pre-treatment DCE-MRI findings). 6. The target breast is expected to fit in the cup of the dedicated MR-HIFU breast system (based on pre-treatment MRI findings). 7. The patient weighs less than 90 kg (restrictment of the HIFU table top). 8. Provide written informed consent and willing to comply with protocol requirements. Exclusion Criteria: Patients will be excluded if any of the following conditions are observed: 1. Her2-positive disease or classic invasive lobular carcinoma (ILC). 2. A treatment plan with curative intent is available. 3. Any prior chemotherapy treatment for invasive breast cancer (previous anti-hormonal therapy is allowed) 4. Any prior therapy with anthracyclines 5. No measurable disease at baseline (according to RECIST 1.1 or PERCIST 1.0) 6. Any concomitant malignancy or previous malignancy in the last 5 years, except basal cell or squamous cell cancer of the skin or in situ carcinoma of the cervix. Subjects with a prior contralateral breast malignancy more than 5 years ago can be included if they did not receive any chemotherapy. 7. Any previous malignancy in the unilateral breast (even if more than 5 years ago) 8. Prior sensitivity (including rash, dyspnea, wheezing, urticarial, or other symptoms) attributed to any liposomal-encapsulated drug. 9. Baseline laboratory values: Absolute Neutrophil Count (ANC) < 1.5 x 10^9/L, Platelets < 75 x 10^9/L, Hemoglobin < 5.6 mmol/L (9 g/dl), Total Bilirubin > 1.5 x upper limit of normal, Alanine Transaminase (ALAT) and Aspartate Transaminase (ASAT) > 2.5 x upper limit of normal >5 x upper limit of normal in case of liver metastases, Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min/1.73m2. 10. World Health Organization Performance Status (WHO-PS) >2. 11. Left Ventricular Ejection Fraction <50% (validated by baseline scan). 12. History of: 1. Acute coronary syndrome in the last year 2. Cerebral vascular accident in the last year 3. Abnormal cardiac stress testing within last 6 months 4. Symptomatic coronary artery disease 5. Uncontrolled hypertension or cardiomyopathy 6. Cardiac valvular surgery or open heart surgery in the last year 7. Known structural heart disease 13. Any condition which may interfere with the hyperthermia portion of the trial such as: functioning cardiac pacemaker; metal plates, rods or prosthesis of the chest wall, breast prosthesis in the treated breast, severe numbness and/or tingling of the chest wall or breast, skin grafts and/or flaps on the breast or chest wall, scar tissue or surgical clips in the HIFU beam path. 14. Active infection 15. Body temperature > 38.0 degrees Celsius on the day of a MR-HIFU treatment. 16. Concurrent use of any of the following prohibited medications within a reasonable wash-out time: protease inhibitors, cyclosporine, carbamazepine, phenytoin, valproic acid, paclitaxel, trastuzumab and other liposomal drugs (Abelect, Ambisome, Nyotran, etc.) or lipid-complexed drugs. 17. Caution will be exercised with all the medications mentioned in appendix C, for interactions are theoretically possible. 18. Contraindications to MR imaging (e.g., pacemaker in situ, severe claustrophobia, metal implants incompatible with the MRI-scan, body size incompatible with MR bore). 19. Contraindications to gadolinium-based contrast agent, including prior allergic reaction to gadolinium-based contrast agent, and/or renal failure. 20. Contraindications to sedation and analgesia with propofol and Remifentanil, including history of Chronic Obstructive Pulmonary Disease (COPD) that results in the inability to perform a physical activity corresponding with a Metabolic Equivalent (MET(57)) of 4; dependence on artificial ventilation at home; sleep apnea or an American Society of Anesthesiologists (ASA) classification ≥4. 21. Inability to lie in prone position. 22. A medical or psychiatric condition or other circumstances which would significantly decrease the chances of understanding the informed consent process, obtaining reliable data, achieving study objectives, or completing the study treatment and/or examinations. |
Outcome
Primary Outcome Measures
1. Incidence of adverse events assessed by CTCAE v 5.0 [From first study treatment (day 1) until the end of study visit between day 161 and 175]
2. Incidence of dose limiting toxicities [From first study treatment (day 1) until the end of study visit between day 161 and 175]
3. Incidence of necessity for dose adjustments, delay or early cessation [From first study treatment (day 1) until the end of study visit between day 161 and 175]
4. Incidence and severity of post-procedural pain [From first study treatment (day 1) until the end of study visit between day 161 and 175]
5. Patient reported tolerability via an adapted version of the Cancer Therapy Satisfaction Questionnaire (CTSQ) [Baseline, day 49 and day 112]
6. Patient reported tolerability via the Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire [Baseline, and on day 14 of each cycle (with a maximum of six 21-day cycles in 18 weeks)]
7. Incidence of cardiotoxity [From first study treatment (day 1) until the end of study visit between day 161 and 175]
8. Description of MR thermometry data (describing the temperatures achieved) [On day 1 (study treatment day) of each cycle (with a maximum of six 21-day cycles in 18 weeks)]
9. Duration of procedures on a treatment day [On day 1 (study treatment day) of each cycle (with a maximum of six 21-day cycles in 18 weeks)]
10. Number of completed cycles with MR-HIFU induced hyperthermia, ThermoDox and cyclophosphamide [From first study treatment (day 1) until the end of study visit between day 161 and 175]
11. The number of cycles in which hyperthermia was sufficient: at least 30 minutes at the target temperature of 40-42°C [From first study treatment (day 1) until the end of study visit between day 161 and 175]
Secondary Outcome Measures
1. Radiological objective response locally on breast Magnetic Resonance Imaging, assessed by RECIST 1.1. [Assessed after 2 cycles and after 6 cycles of the study treatment. Each cycle is 21 days.]
2. Radiological objective response systemically on Computed Tomography, assessed by RECIST 1.1 or (for patients without RECIST-measurable disease) Positron Emission Tomography Computed Tomography, assessed by PERCIST 1.0 [Assessed after 2 cycles and after 6 cycles of the study treatment. Each cycle is 21 days.]
